Ghashghaei, Maryam and Liu, Yilin and Ettles, James and Bombaci, Giuseppe and Ramkumar, Niveditha and Liu, Zongmin and Escano, Leo and Miko, Sandra Spencer and Kim, Yerin and Waldron, Joseph A. and Do, Kim and MacPherson, Kyle and Yuen, Katie A. and Taibi, Thilelli and Yue, Marty and Arsalan, Aaremish and Jin, Zhen and Edin, Glenn and Karsan, Aly and Morin, Gregg B. and Kuchenbauer, Florian and Perna, Fabiana and Bushell, Martin and Vu, Ly P. (2024) Translation efficiency driven by CNOT3 subunit of the CCR4-NOT complex promotes leukemogenesis. Nature Communications, 15: 2340. ISSN 2041-1723

<img xmlns="http://www.w3.org/1999/xhtml" src="https://pub.demo35.eprints-hosting.org/330/1.haslightboxThumbnailVersion/322815.pdf" class="document_preview_tile_thumbnail"/> <span xmlns="http://www.w3.org/1999/xhtml" title="322815.pdf">322815.pdf</span>
322815.pdf - Published Version
Available under License Creative Commons Attribution.

Download (5MB)
Abstract

Protein synthesis is frequently deregulated during tumorigenesis. However, the precise contexts of selective translational control and the regulators of such mechanisms in cancer is poorly understood. Here, we uncovered CNOT3, a subunit of the CCR4-NOT complex, as an essential modulator of translation in myeloid leukemia. Elevated CNOT3 expression correlates with unfavorable outcomes in patients with acute myeloid leukemia (AML). CNOT3 depletion induces differentiation and apoptosis and delayed leukemogenesis. Transcriptomic and proteomic profiling uncovers c-MYC as a critical downstream target which is translationally regulated by CNOT3. Global analysis of mRNA features demonstrates that CNOT3 selectively influences expression of target genes in a codon usage dependent manner. Furthermore, CNOT3 associates with the protein network largely consisting of ribosomal proteins and translation elongation factors in leukemia cells. Overall, our work elicits the direct requirement for translation efficiency in tumorigenesis and propose targeting the post-transcriptional circuitry via CNOT3 as a therapeutic vulnerability in AML.

Information
Library
URI https://pub.demo35.eprints-hosting.org/id/eprint/330
View Item